BLA Acceptance News Likely Misattributed to VERX; No Change to Thesis

What happened

An article from Zacks reports that the FDA accepted Vertex's biologics license application (BLA) for povetacicept in IgA nephropathy with a decision due November 2026. However, the article appears to refer to Vertex Pharmaceuticals (ticker: VRTX), not Vertex Inc. (ticker: VERX), a tax compliance software company covered in the DeepValue report. The DeepValue master report maintains a WAIT rating on VERX with a base case value of $15, driven by its Value Creation Plan and e-invoicing mandates. For VERX, there is no fundamental update from this news, as it is a different company entirely. Investors should disregard this article for VERX and focus on upcoming catalysts like France e-invoicing mandates and Q2 2026 earnings.

Implication

The news has no bearing on Vertex Inc. (VERX). The investment thesis remains unchanged: VERX is a WAIT with catalysts around its Value Creation Plan and e-invoicing rollout in France starting Sept 1, 2026. The next 6-12 months require proof of EBITDA delivery and mandate conversion. The current price at $13.2 offers limited margin of safety. Investors should ignore the BLA news and monitor VERX-specific milestones.

Thesis delta

No change. The article is misattributed; VERX's thesis remains based on tax software growth and cost savings. The WAIT rating persists with no new information.